Neil P. Shah

15.4k total citations · 5 hit papers
53 papers, 8.9k citations indexed

About

Neil P. Shah is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Neil P. Shah has authored 53 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 34 papers in Genetics and 24 papers in Rheumatology. Recurrent topics in Neil P. Shah's work include Chronic Myeloid Leukemia Treatments (36 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Eosinophilic Disorders and Syndromes (23 papers). Neil P. Shah is often cited by papers focused on Chronic Myeloid Leukemia Treatments (36 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Eosinophilic Disorders and Syndromes (23 papers). Neil P. Shah collaborates with scholars based in United States, Germany and France. Neil P. Shah's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Andreas Hochhaus, Charles L. Sawyers, Michele Baccarani, Eric Bleickardt, Timothy P. Hughes, Concepción Boqué, Charles Chuah and John Nicoll and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Neil P. Shah

46 papers receiving 8.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

2006 1.3k citations Moshe Talpaz, Neil P. Shah et al. New England Journal of Medicine profile →
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine profile →
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

2016 621 citations Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology profile →
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine profile →
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

2011 441 citations Hagop M. Kantarjian, Neil P. Shah et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil P. Shah United States	30	7.3k	5.8k	3.9k	1.4k	1.2k	53	8.9k
Michael J. Mauro United States	40	3.9k 0.5×	3.1k 0.5×	2.1k 0.5×	918 0.7×	825 0.7×	234	5.3k
Animesh Pardanani United States	78	13.0k 1.8×	15.2k 2.6×	8.0k 2.1×	1.5k 1.1×	9.7k 8.2×	466	21.6k
Ilene Galinsky United States	32	3.3k 0.4×	1.9k 0.3×	495 0.1×	969 0.7×	2.6k 2.2×	84	5.3k
Margaret Dugan United States	29	1.4k 0.2×	2.2k 0.4×	618 0.2×	2.5k 1.8×	1.9k 1.6×	71	6.2k
Angelo Michele Carella Italy	38	3.0k 0.4×	1.6k 0.3×	233 0.1×	2.8k 2.1×	909 0.8×	234	6.3k
Alexander E. Perl United States	37	3.9k 0.5×	1.6k 0.3×	107 0.0×	942 0.7×	3.2k 2.7×	200	6.3k
Ashutosh Wechalekar United Kingdom	55	1.5k 0.2×	2.3k 0.4×	1.4k 0.4×	2.2k 1.6×	9.3k 7.9×	267	10.5k
Sandra Silberman United States	15	1.1k 0.2×	668 0.1×	810 0.2×	1.8k 1.3×	1.0k 0.9×	38	6.8k
Raoul Tibes United States	34	1.4k 0.2×	771 0.1×	137 0.0×	1.5k 1.1×	3.6k 3.1×	144	5.3k
Vincent Ribrag France	46	962 0.1×	1.7k 0.3×	185 0.0×	4.6k 3.4×	2.0k 1.7×	309	7.9k

Countries citing papers authored by Neil P. Shah

Since Specialization

Citations

This map shows the geographic impact of Neil P. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil P. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil P. Shah more than expected).

Fields of papers citing papers by Neil P. Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil P. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil P. Shah. The network helps show where Neil P. Shah may publish in the future.

Co-authorship network of co-authors of Neil P. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Neil P. Shah. A scholar is included among the top collaborators of Neil P. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil P. Shah. Neil P. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Neil P., et al.. (2025). Identification of potent phytochemical inhibitors against mobilized colistin resistance: Molecular docking, MD simulations, ADMET, and toxicity predictions. 1. 100013–100013. 1 indexed citations

Shah, Neil P., et al.. (2025). Consumer Behavior in the Post-Pandemic Era: Insights from Machine Learning and AI-Driven Analytics. 1–5.

Shah, Neil P., et al.. (2023). Recurrent Acute Pancreatitis in the Setting of Abnormal Pancreaticobiliary Junction. Cureus. 15(10). e47029–e47029. 1 indexed citations

Moroi, Sayoko E., David M. Reed, David S. Sanders, et al.. (2019). Precision medicine to prevent glaucoma-related blindness. Current Opinion in Ophthalmology. 30(3). 187–198. 25 indexed citations

Cortes, Jörge E., Hagop M. Kantarjian, Javier Pinilla‐Ibarz, et al.. (2017). 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 17. S307–S308.

Cortes, Jörge E., Giuseppe Saglio, Hagop M. Kantarjian, et al.. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 34(20). 2333–2340. 621 indexed citations breakdown →

Chatterjee, Chirantan, et al.. (2016). Maximizing Local Value Addition in Indian Mobile Phone Manufacturing: A Practical Phased Approach. SSRN Electronic Journal. 1 indexed citations

Shah, Neil P., François Guilhot, Jörge E. Cortes, et al.. (2014). Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 123(15). 2317–2324. 140 indexed citations

O’Brien, Susan, Camille N. Abboud, Mojtaba Akhtari, et al.. (2012). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 10(1). 64–110. 20 indexed citations

10.

Shah, Neil P., et al.. (2012). Sonography of Supraspinatus Tendon Abnormalities in the Neutral Versus Crass and Modified Crass Positions. Journal of Ultrasound in Medicine. 31(8). 1203–1208. 6 indexed citations

11.

Cortes, Jörge E., Hagop M. Kantarjian, Neil P. Shah, et al.. (2012). Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine. 367(22). 2075–2088. 527 indexed citations breakdown →

12.

Paquette, Ronald, John Nicoll, Meenal Chalukya, et al.. (2011). Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics. 204(7). 392–397. 28 indexed citations

13.

Kantarjian, Hagop M., Neil P. Shah, Jörge E. Cortes, et al.. (2011). Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 119(5). 1123–1129. 441 indexed citations breakdown →

14.

Kantarjian, Hagop M., Neil P. Shah, Andreas Hochhaus, et al.. (2010). Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 362(24). 2260–2270. 1103 indexed citations breakdown →

15.

O’Brien, Susan, Ellin Berman, Hossein Borghaei, et al.. (2009). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 7(9). 984–1023. 175 indexed citations

16.

Mustjoki, Satu, Marja Ekblom, T. Petteri Arstila, et al.. (2009). Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23(8). 1398–1405. 229 indexed citations

17.

Shah, Neil P., Brian J. Skaggs, Susan Branford, et al.. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation. 117(9). 2562–2569. 288 indexed citations

18.

Talpaz, Moshe, Neil P. Shah, Hagop M. Kantarjian, et al.. (2006). Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine. 354(24). 2531–2541. 1288 indexed citations breakdown →

19.

Shah, Neil P., et al.. (2005). Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Annals of Allergy Asthma & Immunology. 94(5). 575–580. 59 indexed citations

20.

Shah, Neil P.. (2005). Loss of Response to Imatinib: Mechanisms and Management. Hematology. 2005(1). 183–187. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact